National Cancer Institute - Cancer.gov

Faculty News

Jung-Min Lee

Jung-Min Lee elected to the American Society for Clinical Investigation

Jung-Min Lee, M.D., Senior Investigator in the Women’s Malignancies Branch, was elected to the American Society for Clinical Investigation. The organization seeks to support scientific efforts, educational needs and clinical aspirations of physician-scientists to improve the health of all people. Lee was selected for her merit as an internationally recognized expert in ovarian cancer and for being a highly respected clinician and physician-scientist. 

Read More
Jung-Min Lee

Jung-Min Lee appointed Senior Investigator at CCR

The CCR community congratulates Jung-Min Lee, M.D., who has been appointed as a Senior Investigator in the Women’s Malignancies Branch. Lee’s research focuses on developing targeted therapies for ovarian carcinoma. Her studies have identified key proteins of DNA damage response pathways as therapeutic targets, opening up possibilities for novel therapies for this disease. Her research also emphasizes the collection of patient samples to better understand treatment response and tumor biology.

Read More
Leah Cook, Ph.D.

Leah Cook appointed Senior Investigator at CCR

The CCR community welcomes Leah M. Cook, Ph.D., who has been appointed as a Senior Investigator in the Cancer Innovation Laboratory. She is a cancer biologist with a focus on metastasis and the metastasis microenvironment. The goal of her research program is to identify mechanisms associated with bone metastatic prostate cancer and specifically, the underpinnings of the immune-tumor bone environment that contribute to metastatic disease.

Read More
TIL Therapy Graphic

First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma

On February 16, 2024, the Food and Drug Administration approved lifileucel (Amtagvi), the first cancer treatment that uses immune cells called tumor-infiltrating lymphocytes (TILs), for some people with advanced melanoma. TIL therapy was pioneered in the 1980s by Steven A. Rosenberg, M.D., Chief of the Surgery Branch, and the final approval of this treatment has taken years of clinical trial research and ongoing partnerships among multiple institutions.

Read More
Steven Rosenberg, M.D.

Steven Rosenberg receives AACR Award for Lifetime Achievement in Cancer Research

The American Association for Cancer Research (AACR) has awarded Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, the AACR Award for Lifetime Achievement in Cancer Research. He is being recognized for his paramount contributions to cancer research and patient care, most notably his pioneering research in establishing cancer immunotherapy as a major treatment strategy for many cancer types. He will receive the award at the 2024 AACR Annual Meeting. 

Read More